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ACTA NEUROPSYCHIATRICA
Association of the leucine-7 to proline-7
variation in the signal sequence of
neuropeptide Y with major depression
Koefoed P, Woldbye DPD, Hansen TvO, Eplov LF, Christiansen SH,
Mors O, Kessing LV, Werge T, Kaipio K, Pesonen U, Fahmy T, Mellerup
E, Jakobsen KD, Hansen ES, Knudsen GM, Bukh JD, Bock C, Lindberg
C, Kristensen AS, Dam H, Nordentoft M, Als TD, Wang AG, Gether U,
Rehfeld JF, Bolwig TG. Association of the leucine-7 to proline-7 variation
in the signal sequence of neuropeptide Y with major depression.
Objective: There is clear evidence of a genetic component in major
depression, and several studies indicate that neuropeptide Y (NPY) could
play an important role in the pathophysiology of the disease. A
well-known polymorphism encoding the substitution of leucine to proline
in the signal peptide sequence of NPY (Leu7Pro variation) was previously
found to protect against depression. Our study aimed at replicating this
association in a large Danish population with major depression.
Method: Leu7Pro was studied in a sample of depressed patients and
ethnically matched controls, as well as psychiatric disease controls with
schizophrenia. Possible functional consequences of Leu7Pro were explored
in vitro.
Results: In contrast to previous studies, Pro7 appeared to be a risk allele
for depression, being significantly more frequent in the depression sample
(5.5%, n = 593; p = 0.009; odds ratio, OR: 1.46) as compared to
ethnically matched controls (3.8%, n = 2912), while schizophrenia
patients (4.1%, n = 503) did not differ. In vitro, the Pro7 substitution
appeared to be associated with reduced levels of NPY without affecting its
mRNA level.
Conclusion: The Leu7Pro variation may increase the risk of major
depression, possibly by affecting the biosynthesis of NPY.
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Significant outcomes
• The Leu7Pro variation of NPY was associated with depression, but not schizophrenia, in a large Danish
sample.
• The ‘Pro7 allele’ was associated with reduced levels of NPY in cell cultures.
• The study is consistent with a role for NPY in the aetiology of depression.
Limitations
• Swedish and Dutch studies reported lower frequency of the “Pro7 allele” in depressed patients opposite
to the finding in the present Danish sample. However, the former studies used different sampling
procedures and control populations.
Introduction
Depression is a complex, severe psychiatric disor-
der with a lifetime prevalence of at least 10% with
clear evidence for a genetic component; thus twin
studies indicate heritability of 40–50% (1,2). Both
clinical and animal studies suggest that neuropep-
tide Y (NPY) plays an important role in depres-
sion (3). For instance, the synthesis of NPY is
decreased in the hippocampus in rodent models of
depression (4–6). Conversely, treatment with antide-
pressant drugs (7–9) and electroconvulsive stimula-
tion increase hippocampal NPY and NPY receptor
expression (10–12) as well as release of NPY (11).
In addition, intracerebral administration of NPY has
antidepressant-like activity in rodents (13,14) and
depressed patients have decreased concentrations of
NPY in the cerebrospinal fluid (CSF) (15,16), sug-
gesting a possible link between shortage of NPY
and predisposition to depression. NPY also causes
anxiolytic-like effects in rodents (17,18). Consistent
with this concept, certain haplotypes of the NPY
gene have been implicated in the regulation of emo-
tions and stress responses in humans (19).
The most thoroughly investigated polymorphism
(rs16139) of several in the NPY gene (20–23) is
located at position 20 T > C from the transcription
start (A in AUG; in the literature sometimes referred
to as 1128 T > C) on chromosome 7p15.1. The
20 T > C polymorphism causes a substitution of
amino acid residue number 7 leucine with proline in
the signal peptide of NPY (Leu7Pro variation) (20).
The Leu7Pro variation has been associated with
high serum cholesterol and low-density lipoprotein
(LDL) cholesterol levels (20), carotid atherosclero-
sis (24), retinopathy in type 2 diabetes (25), high
alcohol consumption and alcoholism (26,27). In one
study with alcoholism, association with depression
was examined, but no association was found (26).
Later, a small study with only 51 patients sug-
gested that the ‘Pro7 allele’ protects against depres-
sion (15), and this was also suggested in two recent
papers (28,29).
The present study aimed at replicating the asso-
ciation between the Leu7Pro variation with major
depression in a large sample of Danish patients. To
determine whether effects were specific for depres-
sion, we also studied the occurrence of Leu7Pro in
patients diagnosed with schizophrenia (psychiatric
disease controls). Moreover, as the functional con-
sequences of carrying the ‘Pro7 allele’ are not clear,
we also explored the effect on levels of NPY peptide
and mRNA in vitro in two different cell lines.
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Materials and methods
Subjects
Control samples. Two groups of controls were
examined: screened controls and population controls.
Screened controls (n = 287) consisted of healthy
subjects of whom 51 were employees or students
from Rigshospitalet University Hospital, and the
rest were control samples collected in earlier stud-
ies (30–32). These were all questioned about the
occurrence of personal or family history (including
grandparent) of depression, anxiety, or other psychi-
atric disorders, and only persons without such history
were included. The mean age of the screened controls
was 48 years (range = 19–84 years, SD = 19) for
males (n = 109) and 48 years (range = 19–85 years,
SD = 18) for females (n = 178). Population con-
trols (n = 2625) consisted of 374 physically healthy
blood donors collected in the Copenhagen area in
2005; a random sample of 451 unrelated individu-
als from the adult Danish population (age unknown)
collected during the late 1980s in the Copenhagen
area; and a large group of 1804 individuals ran-
domly selected from a random sample of individu-
als aged 30–60 years living in the Copenhagen area
participating in a non-pharmacological intervention
study for prevention of ischaemic heart disease (33).
All population controls were anonymous, thus psy-
chiatric clinical state was unknown. The mean age
of the population controls was 48 years (range =
30–66 years, SD = 9) for males (n = 1254) and
47 years (range = 19–65 years, SD = 9) for females
(n = 1371).
Patients with depression. Blood was sampled from
patients diagnosed with major depression indepen-
dently by two trained psychiatrists (n = 593; ICD-10
diagnoses F32-33) that were admitted to psychiatric
departments at hospitals in the Copenhagen area.
The sample consisted of patients collected within the
period 2002–2008 (n = 389; The Danish Psychiatric
Biobank) and 1993–1998 (n = 204; described else-
where (30,31,34)). The mean age of the depressed
patients was 50 years (range = 19–89 years, SD =
15) for males (n = 210) and 48 years (range = 18–93
years, SD = 19) for females (n = 383), respectively.
Additional information on comorbid anxiety disorder
(F40 and F41 in the ICD-10 diagnostic criteria) was
present for a subset of patients (n = 253; 95 males
and 158 females).
Psychiatric disease controls. Blood samples from
patients with schizophrenia were also analysed (n =
503; ICD-10 diagnosis F20). They were sampled in
the Copenhagen area within the period 2002–2007
(The Danish Psychiatric Biobank; n = 302) and in
the Aarhus area in 2002–2005 (Opus Project; n =
201). Of these, 292 were men (mean age = 37, range
= 19–77, SD = 11) and 211 were women (mean age
= 36, range = 18–84, SD = 12). The patients were
described in more details elsewhere (35).
The subjects of the present study were Danish Cau-
casians. Data on the origin of the depressed patients
were available in 277 cases. The majority of these
(90.6%) had both parents born in Denmark. A minor
fragment had one grandparent (7.6%) born outside
Denmark (mainly Germany or Sweden) while 1.8%
had no information on birthplace of grandparents.
More details regarding origin were also available
for blood donor population controls, with a major-
ity (94%) having both parents born in Denmark (36).
A minor fraction had one parent (1.5%) or both par-
ents (0.5%) born outside Denmark in other European
countries while there was no information in 4% with
regard to place of birth of both parents.
The Scientific-Ethical Committees in Denmark as
well as the Danish Data Protection Agency approved
the present study, and all participants gave informed
consent. This study was conducted in accordance
with the Declaration of Helsinki.
Genotyping (rs16139)
Genomic DNA was extracted from peripheral blood
lymphocytes using QIAamp® DNA Blood Mini kit
or FlexiGene DNA kit (Qiagen, Albertslund, Den-
mark) according to the manufacturer’s instructions.
For 528 of the samples, the NPY exon 2 was anal-
ysed at the denaturing high-performance liquid chro-
matography (D-HPLC) wave system (Transgenomic,
Omaha, NE, USA). Fragments showing mutations
were analysed on an ABI PRISM DNA Sequencer
(ABI310 or ABI3730) (Applied Biosystems, Fos-
ter City, CA, USA). The rest of the samples were
analysed by real-time PCR using TaqMan Assay-
by-design genotyping assay (Applied Biosystems).
Each 96-well plate contained two control samples
(one heterozygote (CT) and one homozygote (CC))
as well as one negative control (no template). The
primer and probe sequences, and temperatures used
at the D-HPLC for each fragment are available on
request. The success rate was 99.7%; only subjects
with successful samples were included in the study.
The genotype for 3.2% of the samples was reanalysed
resulting in 100% concordance.
Plasmids, cell cultures and transient DNA transfections
The pGEM-1-NPY plasmid, containing the human
NPY gene, including signal peptide, NPY and
C-terminal peptide of NPY (CPON), was a kind
gift from Professor Thue W. Schwartz, University
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of Copenhagen. The pGEM-1-NPY plasmid was
digested with EcoRI and BamHI and the NPY coding
region was cloned into pcDNA3.1 (Invitrogen, Carls-
bad, CA, USA), generating pcDNA3.1-NPY-Leu7.
Mutagenesis was performed using the QuickChange
mutagenesis kit (Stratagene, La Jolla, CA, USA)
according to the instructions from the manufac-
turer, generating pcDNA3.1-NPY-Pro7. Both con-
structs (the CMV promoter, NPY cDNA and the
poly-A sequence) were verified by sequencing.
The Syrian hamster beta-cell line HIT-T15 (LGC
Standards AB, Boras, Sweden) and human neuroblas-
toma SK-N-MC cells (ATCC, Manassas, VA, USA)
were cultured at 10% CO2 and 37 ◦C in Dulbecco’s
modified Eagle’s medium (with Glutamax, 5 mM
glucose) supplemented with 10% fetal calf serum,
100 units/ml penicillin and 100 μg/ml streptomycin
(Invitrogen). One day before transfection, 8 × 105
cells were seeded in 6-well culture dishes. Cells
were transfected with 8 μg pcDNA3.1, pcDNA3.1-
NPY-Leu7 or pcDNA3.1-NPY-Pro7 using FuGENE
6 (Roche A/S, Hvidovre, Denmark) according to the
manufacturer’s instructions. Forty-eight hours later,
5 ml culture medium was recovered, and the cells
were harvested in PBS/EDTA, pelleted and resus-
pended in 1-ml sterile H2O. Transfection series were
performed in triplicates and carried out at least three
times.
To ensure that transfection efficiency did not vary
significantly between cells transfected with pcDNA3.
1-NPY-Leu7 and pcDNA3.1-NPY-Pro7, quantitative
PCR was performed as follows: transfected HIT-
T15 and SK-N-MC cells were harvested as above
in PBS/EDTA, and washed once in PBS. Nucleospin
Tissue kit (Macherey-Nagel, Du¨ren, Germany) was
subsequently used for DNA purification according to
the manufacturer’s instructions. The amount of puri-
fied plasmid DNA encoding NPY was measured in
96-well plates on an Icycler (Bio-Rad, Grenaa, Den-
mark). Each well contained a mixture of plasmid
DNA, SYBR Green I and 750 nM of forward and
reverse primers. The plasmid DNA was quantified
by two sets of primers recognising the CMV pro-
moter and ampicillin resistance gene, both located
on the transfection plasmid. Relative quantification
was achieved by comparing each sample to in-plate
reference gene controls (glyceraldehyde-3-phosphate
dehydrogenase, GAPDH). Primer sequences are
available on request.
NPY radioimmunoassay
HIT-T15 and SK-N-MC cells were transfected as
described above. The subsequent procedure for
radioimmunoassay was previously described (37).
Cells and culture media were boiled for 20 min and
cell debris was removed by centrifugation. Extracts
were analysed by radioimmunoassay using anti-NPY
antibody (#6730-0204, Biogenesis, Kidlington, UK)
and 125I-labelled NPY (#IM170, GE Healthcare,
Hillerød, DK). The NPY antibody recognised primar-
ily the mid-portion of the molecule, with little or no
cross-reactivity for N-terminal NPY1-9 or C-terminal
NPY 31-36 (Biogenesis).
NPY mRNA determination
Transfected HIT-T15 and SK-N-MC cells (two indi-
vidual transfection series run in triplicates) were har-
vested as above in PBS/EDTA, and washed once in
PBS. Total RNA was purified using RNeasy spin
columns and on-column DNAse treated (Qiagen), to
remove plasmid DNA encoding NPY, which would
otherwise contribute to the final measurement of
NPY mRNA levels. Total RNA (1 μg) was reverse
transcribed using TaqMan RT master mix (Applied
Biosystems) and random hexamers in a 100-μl reac-
tion. Relative quantification of the cDNA was per-
formed in 96-well plates on the iCycler (Bio-Rad).
Each well contained 2 μl of cDNA mixed with 10 μl
of SYBR Green I master mix (Bio-Rad), 0.2 μl
of uracil-N -glycosylase (Epicentre Biotechnologies,
Madison, WI, USA) and 750 nM forward and reverse
primers (MWG Biotech, Ebersberg, Germany). All
samples were run in duplicates. Collected data were
analysed using the iCycler software, and the cycle
threshold (Ct; i.e., the number of cycles necessary
for the studied gene to be linearly expanded) for
each sample was determined. Relative quantification
was achieved by subtracting each Ct sample with the
in-plate Ct of a reference control gene (delta Ct).
The smaller the delta Ct value the more the gene
is expressed compared with in-plate tested reference
gene.
A group of reference genes, that is, GAPDH, beta-
actin, TATA-box binding protein (TBP) and HPRT,
was tested. GAPDH and TBP were found to be
the least regulated genes and were consequently
used for subsequent quantification of mRNA levels.
Water controls and genomic DNA controls were run
simultaneously with the samples on all plates and
did not differ significantly from background. Primer
sequences are available on request.
Data analysis
Genotype and allele frequencies of the 20 T > C
polymorphism were analysed using Fisher’s exact test
(http://www.graphpad.com/quickcalcs/contingency1.
cfm) or chi-squared test. OR and 95% confidence
interval (CI 95%) were calculated using the website
www.hutchon.net/ConfidOR.htm. Logistic regression
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was used to include age and gender as covariates in
the analysis. Other data were analysed using Mann-
Whitney U test, when relevant, following significant
Kruskal-Wallis analysis of variance by ranks. NPY
peptide data and delta Ct values of quantitative PCR
are presented as mean ± standard error of the mean
(SEM). The level of significance was p < 0.05.
Results
Genotyping
In contrast to previous studies, the Leu7Pro varia-
tion was found to be significantly more frequent in
patients with major depression as compared to the
combined control group (p < 0.0004; Table 1). This
effect did not depend on gender. Thus increased fre-
quencies of the Leu7Pro variation were detected in
both males (p = 0.02) and females (p = 0.002) (data
not shown). Similarly, a significantly higher ‘Pro7
allele’ frequency (i.e., MAF, minor allele frequency)
was seen in depressed patients as compared to the
combined control groups (5.5% vs. 3.8%; p = 0.009;
OR = 1.46, 95% CI = 1.10–1.93). This was also
seen when we compared the depressed sample with
the screened controls (p = 0.01; OR = 2.02, 95% CI
= 1.16–3.53) and population controls (p = 0.02; OR
= 1.41, 95% CI = 1.06–1.88), respectively. Com-
paring the combined cases and controls including
schizophrenia disease controls also resulted in over-
all significance (p = 0.033). No significant differ-
ences in the frequency of the Leu7Pro variation were
found between patients with schizophrenia and con-
trol individuals (Table 1). Gender or age did not vary
between genotype groups (p > 0.95 and p > 0.22,
respectively; data not shown).
Consistent with the association of the Leu7Pro
variation with major depression, the genotype fre-
quencies of depressed male or female patients
were not in Hardy-Weinberg equilibrium, also when
including both sexes (p < 0.005, χ2 = 11.53, df =
2). The genotypic distributions for the control group
and psychiatric disease controls were all in Hardy-
Weinberg equilibrium.
When cases (n = 253) were divided into groups
according to comorbid anxiety (F40 or F41 in
the ICD-10 system), no differences were found in
the distribution of the Leu7Pro variation between
patients with or without comorbid anxiety (MAF
6.4 and 6.3%, respectively; p = 0.98). Significantly
more women (56.3%) showed comorbid anxiety as
compared to men (30.5%; p < 0.001).
Transfections and measurements of NPY and its mRNA
To study the potential functional implications of
Leu7Pro, HIT-T15 and SK-N-MC cells were trans-
fected with plasmids encoding either the NPY ‘Leu7
allele’ or the mutant ‘Pro7 allele’. HIT-T15 cells
transfected with the ‘Leu7 allele’ synthesised and
released substantial amounts of NPY peptide as
compared to cells transfected with empty cDNA
(Fig. 1a). In contrast, NPY peptide concentrations
were significantly lower in cell extracts (68% reduc-
tion; p = 0.0007) and cell media extracts (48%
reduction; p = 0.003) from HIT-T15 cells trans-
fected with cDNA carrying the Pro7 substitution as
compared to HIT-T15 cells carrying the Leu7 plas-
mid. In the SK-N-MC cell line, NPY peptide concen-
trations appeared substantially lower than in HIT-T15
cells in cell extracts where the NPY concentration
was not consistently above the assay detection limit
(data not shown). However, as in HIT-T15 cells, the
NPY concentrations were found to be significantly
lower (34% reduction; p = 0.019) in cell media
extracts from SK-N-MC cells transfected with Pro7
mutant as compared to the Leu7 cDNA (Fig. 1c). As
shown in Fig. 1a and c both cell types had a low
level of endogenous NPY secretion.
Table 1. Distribution of the Leu7Pro variation (T/C) (rs16139)
Genotype
n L7/L7 (TT) n (%) L7/P7 (TC) n (%) P7/P7 (CC) n (%) p value* MAF† (C) % p value‡ OR [95% CI]
Control samples
Screened controls 287 271 (94.4) 16 (5.6) 0 (0.0) 2.8
Population controls 2625 2420 (92.2) 203 (7.7) 2 (0.2) 0.38 3.9 0.21 ND
Case-control sample
Combined controls 2912 2691 (92.4) 219 (7.5) 2 (0.1) 3.8
Depressed cases 593 534 (90.1) 53 (8.9) 6 (1.0) 0.0004 5.5 0.009 1.46 [1.10–1.93]
Psychiatric controls
Schizophrenia 503 462 (91.8) 41 (8.2) 0 (0.0) 0.70 4.1 0.36 ND
OR, odds ratio; CI, confidence interval; ND, not determined.
*Fisher’s exact test between cases and controls, significant results are presented in bold.
†MAF: minor allele frequency (C-allele; Pro7 (P7) variant).
‡Chi-square test between cases and controls, significant results are presented in bold.
5
Koefoed et al.
60
80
100
120
140
Leu7
Pro7 mutant
Empty cDNA
Cell extracts Media extracts
-6
-5
-4
HIT-T15 cells
SK-N-MC cells
(a)
(b)
(c)
(d)
10
15
-6
-5
-4
-3
-2
Leu7
Pro7 mutant
Empty cDNA
†
N
PY
 c
on
ce
nt
ra
tio
n 
[n
M]
N
PY
 m
R
N
A
 le
ve
ls
[D
elt
a C
t r
ela
tiv
e t
o G
AP
DH
]
0
1
Media extracts
-1
0
20
40
N
PY
 c
on
ce
nt
ra
tio
n 
[n
M]
0
0.2
***
**
-3
-2
-1
0
N
PY
 m
R
N
A
 le
ve
ls
[D
elt
a C
t r
ela
tiv
e t
o G
AP
DH
]
Leu7
Pro7 mutant
Leu7
Pro7 mutant
Fig. 1. Levels of NPY peptide and mRNA in vitro in cells transfected with the Leu7 NPY gene, the Pro7 mutant and cDNA
empty of the NPY gene. NPY peptide concentrations as measured with radioimmunoassay (RIA) in cell and/or media extracts from
(a) 800 000 HIT-T15 and (c) 800 000 SK-N-MC cells carrying the Pro7 mutant were significantly lower than in those carrying the
Leu7 NPY gene. Levels of NPY peptide in SK-N-MC cell extracts are not shown as they were not consistently above the assay
detection limit. In contrast, NPY mRNA levels measured using quantitative PCR did not differ between Leu7 and Pro7 transfected
cells, neither in HIT-T15 (b) nor in SK-N-MC (d) cells. Data are mean (±SEM) from individual transfection series performed
in triplicates (n = 9–12, RIA; n = 6, quantitative PCR). ∗∗∗p < 0.001, ∗∗p < 0.01, †p < 0.02 versus WT, Mann-Whitney U test
following significant Kruskal-Wallis analysis of variance by ranks.
In contrast, quantitative PCR using GAPDH as ref-
erence gene showed that NPY mRNA levels were
similar in Pro7 and Leu7 transfected cells of both
studied cell lines (Fig. 1b, d), indicating that the
reduction in NPY levels in mutant transfected cells
did not result from a decrease in NPY gene expres-
sion. Similar results were obtained using TBP as
reference gene (data not shown). The fact that NPY
mRNA levels were similar in Pro7 and Leu7 trans-
fected cells would suggest that transfection efficiency
was also similar. As further evidence that differences
in NPY concentrations in Pro7 and Leu7 transfected
cells did not result from a decrease in transfection
efficiency, we also tested transfection efficiency in
the cell lines by measuring levels of two DNA seg-
ments located on the transfection plasmid: the CMV
promoter and ampicillin resistance gene. Quantitative
PCR confirmed that there were, indeed, no significant
differences in transfection efficiency in any of the
two cell lines as revealed by the following delta
Ct values (mean ± SEM; GAPDH as reference
gene): CMV promotor wild-type (−9.3 ± 0.1) ver-
sus mutant (−9.0 ± 0.2; p = 0.15); ampicillin resis-
tance gene wild-type (−9.0 ± 0.2) versus mutant
(−8.6 ± 0.2; p = 0.17).
Discussion
The present study shows that the Leu7Pro varia-
tion may be associated with increased risk of major
depression. The frequency of Leu7Pro was not sig-
nificantly different from the control population in
psychiatric disease control patients with schizophre-
nia. We also show in two cell lines in vitro, that the
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Leu7Pro variation can be associated with decreased
levels of NPY protein, apparently without accompa-
nying changes in NPY mRNA levels.
Our results are not consistent with previous stud-
ies, reporting either no difference between depressed
patients and controls (26) or decreased frequency of
Leu7Pro variation in depression (15,28,29). Thus our
study suggests Pro7 to be a risk allele as opposed to
a protective allele in previous studies. The lack of
agreement between the present and previous studies
is puzzling. Smaller sample sizes could play a role.
For instance, Lappalainen et al. (26), who reported
no association, studied a smaller sample of 122
depressed patients and the frequency of Leu7Pro in
this study was low in the control group (2.0%) com-
pared to that of the present study (3.8%). Similarly,
Heilig et al. (15) reported the opposite of the present
study in an even smaller Swedish sample (n = 51) of
treatment resistant depression. However, decreased
frequency of the ‘Pro7 allele’ was also found in a
larger depression sample (n = 461) from a Swedish
population (28), and this was confirmed in a recent
replication study using a Dutch population (GAIN;
n = 1862) (p = 0.034; OR = 0.73) (29).
Differences in ethnic origin of the subjects could
also contribute to apparent discrepancies between our
study and previous studies. Thus the large Swedish
population (28) was taken from a large cohort of
Swedish citizens, in which up to 10% were born out-
side Sweden (38), with no information on place of
birth, which might indicate that some of the cases
were of non-Caucasian origin. In the large study by
Bosker et al. the individuals were of Dutch or West-
ern European origin (29). Given the north-to-south
gradient of decreasing frequency of the ‘Pro7 allele’
with reported frequencies in Dutch (3.5%) and Ger-
man (3.6%) versus Swedish (3.9–4.6%) and Finnish
(5.8–6.9%) populations and, more importantly, the
absence of the ‘Pro7 allele’ in non-Caucasian popu-
lations (39), it is important that ethnicity of patients
and controls is similar. All our patients were Cau-
casians born in Denmark and only a minority of their
parents were born outside Denmark in another Euro-
pean country. To clarify this issue further future stud-
ies might explore ethnicity in more depth by genetic
stratification using ethnically specific marker genes.
Differences in sampling procedures could also
be involved. Thus our patients were diagnosed by
trained psychiatrists and recruited among patients
hospitalised at psychiatric departments. In contrast,
the Dutch cases (29) were recruited from mental
health-care organisations, primary care and commu-
nity samples, and the Swedish cases (28) were iden-
tified on the basis of self-reported questionnaires.
Yet another explanation could be differences in
diagnostic criteria in the different studies. We
collected patients in our sample based on a diagno-
sis of major depression in hospitalised patients (F32
or F33 in the ICD-10 system), whereas the Dutch
cases were included on the basis of a lifetime diag-
nosis of major depression (DSM-IV system) as diag-
nosed through the Composite International Diagnos-
tic Interview (CIDI Version 2.1.12) (29). Moreover,
the Swedish study (28), in addition to major depres-
sion, also included patients with dysthymia and
mixed anxiety depression. We found no difference
in genotype and allele frequencies between patients
with comorbid anxiety as compared to patients with-
out, suggesting that our association of Leu7Pro with
depression is not influenced by comorbid anxiety.
Other more common variations in the NPY gene
have been studied (19,22,34,40). The T allele in
the promoter polymorphism −399C>T (rs16147)
has been associated with decreased expression of
NPY (22) and diplotypes containing the NPY-399C
allele resulted in low expression of NPY and
predicted emotional regulation in healthy individu-
als (19). The low expression diplotypes were over-
represented in depressed subjects and also found
to increase neural responsivity to negative stimuli
within the medial prefrontal and anterior cingulate
cortices (41). However, the diplotype analysis did
not include the Pro7 variant; therefore the impact
of Leu7Pro was not analysed in the latter study.
The signal sequence in prepro-peptides has multi-
ple functions in targeting and subsequent transloca-
tion or insertion of proteins into the membrane of the
endoplasmatic reticulum (ER) (42). During transport
into the ER lumen, signal sequences are often cleaved
from the precursor protein. Secondary and tertiary
structure of the signal sequence of preproNPY could
be dramatically altered by the Leu7Pro substitu-
tion, as proline easily forms brakes and kinks in
alpha-helical structures (43). Therefore, it could be
expected that the Leu7Pro variation could lead to
modifications in the formation, storage, and release
of mature NPY. Consistent with this view, previous
studies have reported that substitution of leucine with
proline in the signal peptide may be associated with
drastic decreases in expression of the mature protein.
For instance, Lanza et al. (44) showed that leucine
for proline substitution (also in position 7) in the sig-
nal peptide of platelet glycoprotein IX (GPIX) was
associated with abolished GPIX synthesis. Likewise,
leucine with proline substitution in the signal pep-
tide of calcium-sensing receptor (CASR) resulted in
markedly reduced levels of CASR that appeared to
be due to a failure of insertion into the ER (45).
Studying the HIT-T15 and SK-N-MC cell lines,
the present study shows that the ‘Pro7 allele’ could
be associated with a decrease in both intra- and
extracellular levels of NPY. A previous study using
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PC12 cells did not find that the Leu7Pro variation
affected the site of cleavage and targeting or uptake
of NPY into the ER (46). In addition, another study
found increased synthesis and secretion of NPY in
the Pro7 mutant when co-transfected with ‘Leu7
constructs’ (47). The reason for these apparent dis-
crepancies is not clear. Perhaps the effect of the
Leu7Pro variation could be cell-type specific. Thus
the effect of Leu7Pro appeared to be more pro-
nounced in HIT-T15 as compared to SK-N-MC cells,
and different cell types (PC12 cells, ArT-20 cells and
mouse chromaffin cells) were used in the other stud-
ies (46,47). Nonetheless, Leu7/Pro7 heterozygous
individuals had decreased concentrations of NPY in
plasma (48,49) in accordance with the present in
vitro findings of decreased intra- and extracellular
NPY levels. However, an increase in plasma NPY
concentrations has been reported during exercise of
Leu7/Pro7 individuals as compared to Leu7/Leu7
controls (50). Since only heterozygous individuals
were tested in the latter study, it is not directly com-
parable to our in vitro data. Thus the HIT-T15 and
SK-N-MC cell lines are basically a ‘homozygous sit-
uation’, expressing only the Pro7 allele.
It is not known how the Leu7Pro variation might
increase the risk of depression. However, the present
finding that the Pro7 substitution was associated with
impaired NPY synthesis and decreased extracellular
levels in vitro is consistent with data from the liter-
ature, that central administration of NPY has actions
that may antagonise key symptoms of depression,
including orexigenic, sleep inducing, anti-stress and
anxiolytic effects (3,51). In addition, central injec-
tion of NPY induces antidepressant-like effects in
experimental animal models (14,52) and depressed
patients have significantly lower concentrations of
NPY in CSF (15,16). Conversely, several types of
antidepressant treatments cause increases in NPY
gene expression in rodents or in NPY concentra-
tion in CSF of human patients (11,12,53). More-
over, animal and human data indicate that NPY
exerts widespread effects on the release of hypotha-
lamic hormones implicated in the pathophysiology
of depression, including corticotropin-releasing hor-
mone (CRH), adrenocorticotropic hormone (ACTH)
and gonadotropins (3).
In conclusion, the present study shows that carry-
ing the ‘Pro7 allele’ in the signal sequence of NPY
may be a risk factor for major depression in the Dan-
ish population. Our results were based on a large
cohort of patients, two types of controls, more nar-
row diagnostic criteria, which could account for the
results that are in the opposite direction from previ-
ous studies. In vitro, the Leu7Pro variation showed
functional consequences in the form of impaired
NPY biosynthesis and reduced extracellular levels
consistent with previously described antidepressant
effect of NPY in the brain.
Acknowledgements
We thank Merete E. Nielsen, Birgit H. Hansen, Stine Østergaard,
and Bente Bennike for excellent technical assistance. We also
thank Preben B. Mortensen for access to some of the patient sam-
ples. Funding of this study was provided by The Broedrene Hart-
manns Foundation, Danish Psychiatric Research Foundation, H:S
Research Council, Ivan Nielsen’s Foundation, John and Birthe
Meyer Foundation, Pool for Support of Psychiatric Research in
the County of Aarhus, and Stanley Medical Research Institute,
and Center for Pharmacogenomics, University of Copenhagen.
All authors declare that they have no conflicts of interest.
References
1. Kessing LV. Gender differences in patients presenting with
a single depressive episode according to ICD-10. Soc
Psychiatry Psychiatr Epidemiol 2005;40:197–201.
2. Levinson DF. The genetics of depression: a review. Biol
Psychiatry 2006;60:84–92.
3. Redrobe JP, Dumont Y, Quirion R. Neuropeptide Y
(NPY) and depression: from animal studies to the human
condition. Life Sci 2002;71:2921–2937.
4. Husum H, Vasquez PA, Mathe AA. Changed concen-
trations of tachykinins and neuropeptide Y in brain of
a rat model of depression: lithium treatment normalizes
tachykinins. Neuropsychopharmacology 2001;24:183–191.
5. Mathe´ AA, Jimenez PA, Theodorsson E, Stenfors C.
Neuropeptide Y, neurokinin A and neurotensin in brain
regions of Fawn-Hooded “depressed”, Wistar, and Sprague-
Dawley rats. Effects of electroconvulsive stimuli. Prog
Neuropsychopharmacol Biol Psychiatry 1998;22:529–546.
6. Jimenez-Vasquez PA, Mathe´ AA, Thomas JD, Riley EP,
Ehlers CL. Early maternal separation alters neuropeptide Y
concentrations in selected brain regions in adult rats. Brain
Res Dev Brain Res 2001;131:149–152.
7. Caberlotto L, Fuxe K, Overstreet DH, Gerrard P,
Hurd YL. Alterations in neuropeptide Y and Y1 recep-
tor mRNA expression in brains from an animal model of
depression: region specific adaptation after fluoxetine treat-
ment. Brain Res Mol Brain Res 1998;59:58–65.
8. Heilig M, Wahlestedt C, Ekman R, Widerlo¨v E.
Antidepressant drugs increase the concentration of neu-
ropeptide Y (NPY)-like immunoreactivity in the rat brain.
Eur J Pharmacol 1988;147:465–467.
9. Mathe´ AA, Jousisto-Hanson J, Stenfors C, Theodor-
sson E. Effect of lithium on tachykinins, calcitonin gene-
related peptide, and neuropeptide Y in rat brain. J Neurosci
Res 1990;26:233–237.
10. Stenfors C, Theodorsson E, Mathe´ AA. Effect of
repeated electroconvulsive treatment on regional concen-
trations of tachykinins, neurotensin, vasoactive intestinal
polypeptide, neuropeptide Y, and galanin in rat brain.
J Neurosci Res 1989;24:445–450.
11. Christensen DZ, Olesen MV, Kristiansen H,
Mikkelsen JD, Woldbye DPD. Unaltered neuropeptide
Y (NPY)-stimulated [35S]GTPγ S binding suggests a net
increase in NPY signalling after repeated electroconvulsive
seizures in mice. J Neurosci Res 2006;84:1282–1291.
12. Mikkelsen JD, Woldbye DPD. Accumulated increase in
neuropeptide Y and somatostatin gene expression of the
8
Leu7Pro variation in major depression
rat in response to repeated electroconvulsive stimulation.
J Psychiatr Res 2006;40:153–159.
13. Husum H, Mikkelsen JD, Hogg S, Mathe´ AA. Mørk A.
Involvement of hippocampal neuropeptide Y in mediating
the chronic actions of lithium, electroconvulsive stimulation
and citalopram. Neuropharmacology 2000;39:1463–1473.
14. Redrobe JP, Dumont Y, Fournier A, Quirion R.
The neuropeptide Y (NPY) Y1 receptor subtype mediates
NPY-induced antidepressant-like activity in the mouse
forced swimming test. Neuropsychopharmacology 2002;26:
615–624.
15. Heilig M, Zachrisson O, Thorsell A et al. Decreased
cerebrospinal fluid neuropeptide Y (NPY) in patients with
treatment refractory unipolar depression: preliminary evi-
dence for association with preproNPY gene polymorphism.
J Psychiatr Res 2004;38:113–121.
16. Widerlo¨v E, Lindstrom LH, Wahlestedt C, Ekman R.
Neuropeptide Y and peptide YY as possible cerebrospinal
fluid markers for major depression and schizophrenia,
respectively. J Psychiatr Res 1988;22:69–79.
17. Bannon AW, Seda J, Carmouche M et al. Behavioral
characterization of neuropeptide Y knockout mice. Brain
Res 2000;868:79–87.
18. Sørensen G, Lindberg C, Wo¨rtwein G, Bolwig TG,
Woldbye DPD. Different roles for neuropeptide Y Y1 and
Y5 receptors in anxiety and sedation. J Neurosci Res 2004;
77:723–729.
19. Zhou Z, Zhu G, Hariri AR et al. Genetic variation in
human NPY expression affects stress response and emotion.
Nature 2008;452:997–1001.
20. Karvonen MK, Pesonen U, Koulu M et al. Association
of a leucine(7)-to-proline(7) polymorphism in the signal
peptide of neuropeptide Y with high serum cholesterol and
LDL cholesterol levels. Nat Med 1998;4:1434–1437.
21. Okubo T, Harada S. Polymorphism of the neuropeptide Y
gene: an association study with alcohol withdrawal. Alcohol
Clin Exp Res 2001;25(6 Suppl):59S–62S.
22. Itokawa M, Arai M, Kato S et al. Association between
a novel polymorphism in the promotor region of the
neuropeptide Y gene and schizophrenia in humans. Neurosci
Lett 2003;347:202–204.
23. Mottagui-Tabar S, Prince JA, Wahlestedt C, Zhu G,
Goldman D, Heilig M. A novel single nucleotide poly-
morphism of the neuropeptides Y (NPY) gene associated
with alcohol dependence. Alcohol Clin Exp Res 2005;29:
702–707.
24. Niskanen L, Karvonen MK, Valve R et al. Leucine 7
to proline 7 polymorphism in the neuropeptide Y gene is
associated with enhanced carotid atherosclerosis in elderly
patients with type 2 diabetes and control subjects. J Clin
Endocrinol Metab 2000;85:2266–2269.
25. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M
et al. Leucine 7 to proline 7 polymorphism in the neuropep-
tide Y gene is associated with retinopathy in type 2 diabetes.
Exp Clin Endocrinol Diabetes 2000;108:235–236.
26. Lappalainen J, Kranzler HR, Malison R et al. A func-
tional neuropeptide Y Leu7Pro polymorphism associated
with alcohol dependence in a large population sample from
the United States. Arch Gen Psychiatry 2002;59:825–831.
27. Kauhanen J, Karvonen MK, Pesonen U et al. Neuropep-
tide Y polymorphism and alcohol consumption in middle-
aged men. Am J Med Genet 2000;93:117–121.
28. Sjo¨holm LK, Melas PA, Forsell Y, Lavebratt C. Pre-
proNPY Pro7 protects against depression despite exposure
to environmental risk factors. J Affect Disord 2009;118:
124–130.
29. Bosker FJ, Hartman CA, Nolte IM et al. Poor replica-
tion of candidate genes for major depressive disorder using
genome-wide association data. Mol Psychiatry 2011;16:
516–532.
30. Kessing LV, Jørgensen OS. Apolipoprotein E-ε4 fre-
quency in affective disorder. Biol Psychiatry 1999;45:
430–434.
31. Mellerup E, Bennike B, Bolwig T et al. Platelet sero-
tonin transporters and the transporter gene in control sub-
jects, unipolar patients and bipolar patients. Acta Psychiatr
Scand 2001;103:229–233.
32. Haugboel S, Pinborg LH, Arfan HM et al. Reproducibil-
ity of 5-HT2A receptor measurements and sample size esti-
mations with [18F]altanserin PET using a bolus/infusion
approach. Eur J Nucl Med Mol Imaging 2007;34:910–915.
33. Jørgensen T, Borch-Johnsen K, Thomsen TF et al. A
randomized non-pharmacological intervention study for
prevention of ischaemic heart disease: baseline results
Inter99. Eur J Cardiovasc Prev Rehabil 2003;10:377–386.
34. Lindberg C, Koefoed P, Hansen ES et al. No association
between the – 399 C>T polymorphism of the neuropeptide
Y gene and schizophrenia, unipolar depression or panic
disorder in a Danish population. Acta Psychiatr Scand 2006;
113:54–58.
35. Koefoed P, Hansen TVO, Woldbye DPD et al. An intron
1 polymorphism in the CCK-A receptor gene associated
with schizophrenia in males. Acta Psychiatr Scand 2009;
120:281–287.
36. Hansen T, Olsen L, Lindow M et al. Brain expressed
microRNAs implicated in schizophrenia etiology. PLoS One
2007;12:e873.
37. Rehfeld JF. Radioimmunochemical analysis of neuropep-
tides based on general characteristics of the analyte. Trends
Analyt Chem 1989;8:102–106.
38. Ha¨llstro¨m T, Damstro¨m-Thakker K, Forsell Y,
Lundberg I, Tingho¨g P. The Part study. A population
based study of mental health in the Stockholm county: study
design. 2003. http://www.folkhalsoguiden.se/upload/Psykisk
%20H%c3%a4lsa/PARTs%20tekniska%20rapport.pdf [acc-
essed on April 2011].
39. Ding B. Distribution of the NPY 1128C allele fre-
quency in different populations. J Neural Transm 2003;110:
1199–1204.
40. Domschke K, Dannlowski U, Hohoff C et al. Neuropep-
tide Y (NPY) gene: impact on emotional processing and
treatment response in anxious depression. Eur Neuropsy-
chopharmacol 2010;20:301–309.
41. Mickey BJ, Zhou Z, Heitzeg MM et al. Emotion process-
ing, major depression, and functional genetic variation of
neuropeptide Y. Arch Gen Psychiatry 2011;68:158–166.
42. Hegde RS, Bernstein HD. The surprising complexity of
signal sequences. Trends Biochem Sci 2006;31:563–571.
43. Fitches AC, Appleby R, Lane DA, De SV, Leone G,
Olds RJ. Impaired cotranslational processing as a mech-
anism for type I antithrombin deficiency. Blood 1998;92:
4671–4676.
44. Lanza F, DeLaSalle C, Baas MJ et al. A Leu7Pro muta-
tion in the signal peptide of platelet glycoprotein (GP)IX
in a case of Bernard-Soulier syndrome abolishes surface
expression of the GPIb-V-IX complex. Br J Haematol
2002;118:260–266.
9
Koefoed et al.
45. Pidasheva S, Canaff L, Simonds WF, Marx SJ, Hendy
GN. Impaired cotranslational processing of the calcium-
sensing receptor due to signal peptide missense mutations
in familial hypocalciuric hypercalcemia. Hum Mol Genet
2005;14:1679–1690.
46. Ding B, Kull B, Liu Z et al. Human neuropeptide Y
signal peptide gain-of-function polymorphism is associated
with increased body mass index: possible mode of function.
Regul Pept 2005;127:45–53.
47. Mitchell GC, Wang Q, Ramamoorthy P, Whim MD. A
common single nucleotide polymorphism alters the synthe-
sis and secretion of neuropeptide Y. J Neurosci 2008;28:
14428–14434.
48. Kallio J, Pesonen U, Jaakola U, Karvonen MK,
Helenius H, Koulu M. Changes in diurnal sympathoa-
drenal balance and pituitary hormone secretion in sub-
jects with Leu7Pro. J Clin Endocrinol Metab 2003;88:
3278–3283.
49. Jaakkola U, Kuusela T, Jartti T et al. The Leu7Pro
polymorphism of preproNPY is associated with decreased
insulin secretion, delayed ghrelin suppression, and increased
cardiovascular responsiveness to norepinephrine during oral
glucose tolerance test. J Clin Endocrinol Metab 2005;90:
3646–3652.
50. Kallio J, Pesonen U, Kaipio K et al. Altered intracellular
processing and release of neuropeptides Y due to leucine
7 to proline 7 polymorphism in the signal peptide of
preproneuropeptide Y in humans. FASEB J 2001;15:
1242–1244.
51. Heilig M. The NPY system in stress, anxiety and depres-
sion. Neuropeptides 2004;38:213–224.
52. Ishida H, Shirayama Y, Iwata M et al. Infusion of
neuropeptide Y into CA3 region of hippocampus produces
antidepressant-like effect via Y1 receptor. Hippocampus
2007;17:271–280.
53. Nikisch G, Agren H, Eap CB, Czernik A, Baumann P,
Mathe´ AA. Neuropeptide Y and corticotropin-releasing
hormone in CSF mark response to antidepressive treat-
ment with citalopram. Int J Neuropsychopharmacol 2005;8:
403–410.
10
